Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
HOME > BUSINESS
BUSINESS
- PeptiDream, Takeda Expected to Select 1st Oligo-PDC Candidate in 2023
December 16, 2022
- Eisai, Washington University to Team Up on Neurodegenerative Disease Therapies
December 16, 2022
- Twymeeg Most Promoted Drug in GP Market for 4 Months Straight in October: Intage
December 16, 2022
- Sunovion Offloads Lunesta to Woodward Pharma
December 16, 2022
- Takeda’s HAE Drug Takhzyro Enjoying Positive Uptake in Japan: Exec
December 15, 2022
- Daiichi Sankyo Plots Further Growth with Enhertu Follow-Ons, Eyes Next-Gen ADCs
December 15, 2022
- Bayer Files Xarelto for Congenital Heart Disease after Fontan Procedure in Japan
December 15, 2022
- Total Sales of 25 Japan Drug Makers Up 12.9% in 1st Half, Global Players Fare Well While SMEs Falter
December 15, 2022
- Ono, PrecisionLife Ink Multi-Target R&D Collab
December 15, 2022
- Bribery Scandal Emerges for Hiroshima University Doctor over Ono’s Glactiv
December 14, 2022
- Takeda Puts Up US$4 Billion for Nimbus’ TYK2 Immune Therapy
December 14, 2022
- Chugai’s Appeal Bid for Edirol Method-of-Use Patent Dismissed
December 14, 2022
- NDA for Cefiderocol Accepted in Taiwan: Shionogi
December 14, 2022
- Mejii Kicks Off Japan PIII for Arcturus’ COVID mRNA Vaccine
December 14, 2022
- Enhertu Filed for HER2 Mutant Metastatic NSCLC: Daiichi Sankyo
December 14, 2022
- Daiichi Sankyo’s TROP2-Directed ADC Shows Promising Data for Triple Negative Breast Cancer
December 13, 2022
- Estimated 1,024 Patients Took Xocova in First 11 Days: Shionogi
December 13, 2022
- RaQualia, DWTI Tie Up on Eye Disease Drug Research
December 13, 2022
- Minimum Age for Moderna Boosters Lowered to 12 Years Old in Japan
December 13, 2022
- Astellas CEO Vows Bold Investment in Targeted Protein Degradation to Fuel Drug Discovery
December 12, 2022
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…